Severe Intraocular Infection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02818062

Enrollment

263

Registered

2016-06-29

Start date

2008-01-31

Completion date

2011-09-30

Last updated

2016-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endophthalmitis

Keywords

Endophthalmitis, Cytokines, Chemokines, Inflammation, Regulation

Brief summary

The host-immune reaction to infection is essential for the comprehension of the disease and the development of new therapies. The aim of the study is to describe intraocular cytokines network in aqueous humor using multiplex immunoassay, during severe intraocular infection.

Interventions

BIOLOGICALCytokines dosage in Aqueous humor

Specify details not covered in associated Arm Description.

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Post-operative endophthalmitis * Cataract

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Intraocular cytokine network. Intraocular levels of 27 cytokines	Once in the 24 hours following the admission	Cytokines and chemokines levels in Aqueous humor (AqH) are measured with the Bio-Plex® Multiplex System human Cytokine 27-Plex Panel assay (Bio-Rad, Marne-la-Coquette, France). The immune mediators were classified in five categories: (a) proinflammatory mediators: (IL-6 and monocyte chemoattractant protein (MCP-1), (b) type 1 cytokines: IL-2, IL-12(p70), Interferon (IFN-γ), and tumor necrosis factor-α (TNF-α), (c) type 2 cytokines: IL-4, IL-10 and IL-13, (d) T-regulatory cytokine: IL-10 and (e) Th-17 cytokine: IL-17. The cytokine and chemokine assay plate layout consisted of a standard series in duplicate (1 to 32 000 pg/ml), four blank wells and 20 μl duplicates of pooled AqH samples, diluted to 50 μl with BioPlex mouse serum diluent. The BioPlex® method was performed as recommended by the manufacturer and previously published studies. Data were analyzed with Bio-Plex Manager software® V 1.1 (Bio-Rad).

Secondary

Measure	Time frame	Description
Visual acuity	Once in the 24 hours following the admission, then 3 months, 6 months and 1 year	E Snellen Conversion in LogMAR unit

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026